title: MYEOV is a prognostic factor in multiple myeloma.
abstract: OBJECTIVE
  Multiple myeloma is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells within the bone marrow. This disease remains incurable despite major treatment improvements. However, gene expression profiling of multiple myeloma cells (MMC) may lead to identification of new therapeutic targets.
  
  
  METHODS
  Using Affymetrix microarrays, we identified the overexpression of the MYEOV gene in MMC of 171 patients with newly diagnosed multiple myeloma compared to normal plasma cells.
  
  
  RESULTS
  The MYEOV gene was present (Affymetrix call) in 79% of MMC and in 15% of normal plasma cells. MYEOV gene is not expressed in cells of the patients' bone marrow environment. The downregulation of MYEOV gene reduced the growth of a MYEOV(present) myeloma cell line, unlike a MYEOV(absent) one. Patients with MYEOV(absent) MMC have an increased event-free survival compared to patients with MYEOV(present) MMC, after high-dose therapy and stem cell transplantation and a trend for increased overall survival. In a Cox proportional hazard model, MYEOV expression in MMC is predictive for event-free survival for patients independently of International Staging System stage, t(4;14) translocation, albumin, or B2M serum levels. A knockout of MYEOV significantly reduced the growth of MMC.
  
  
  CONCLUSIONS
  Thus, MYEOV expression is a prognostic factor for patients with multiple myeloma, in part through a role of MYEOV in the control of MMC proliferation.
authors.affiliation: CHU Montpellier, Institute of Research in Biotherapy, Hopital St Eloi, Av. Augustin Fliche, Montpellier Cedex 5, France.
authors.forename: Jerome
authors.initials: J
authors.lastname: Moreaux
authors.forename: Dirk
authors.initials: D
authors.lastname: Hose
authors.forename: Amélie
authors.initials: A
authors.lastname: Bonnefond
authors.forename: Thierry
authors.initials: T
authors.lastname: Reme
authors.forename: Nicolas
authors.initials: N
authors.lastname: Robert
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Bernard
authors.initials: B
authors.lastname: Klein
mesh_terms: D020869:Gene Expression Profiling; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C407245:MYEOV protein, human; D011518:Proto-Oncogene Proteins